跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TRELEGY ELLIPTA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TRELEGY ELLIPTA
Authorized
STANDARD
TRELEGY ELLIPTA
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d9b668ee1061c17d
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
d9b668ee1061c17d
Drug Approval Canada Name
TRELEGY ELLIPTA
Product Name
TRELEGY ELLIPTA
Status
Marketed
Status Date
2021-09-13
Original Market Date
2021-09-13
Din
02515776
Drug Class
Human
Dosage Form
Powder
Route Of Administration
Inhalation
Schedule
Prescription
Ahfs
12:12.08.12
Atc Original
R03AL08 VILANTEROL, UMECLIDINIUM BROMIDE AND FLUTICASONE FUROATE
Atc Name
r 03 al 08
Aig Number
0360150002
Company Name
GlaxoSmithKline Inc
Company Address
800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
FLUTICASONE FUROATE
200 MCG / ACT
UMECLIDINIUM (UMECLIDINIUM BROMIDE)
62.5 MCG / ACT
VILANTEROL (VILANTEROL TRIFENATATE)
25 MCG / ACT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d9b668ee1061c17d
Type
Standard
Back to Health Canada Approvals